By Dana Jacoby
Reactive medicine is expensive medicine. Here’s what the data says about the alternative.
American healthcare has a math problem.
The country now spends roughly $4.9 trillion a year on health, and 90% of that goes toward people living with chronic and mental health conditions—most of which are preventable, manageable, or detectable far earlier than they typically are.
That gap between what we spend treating disease and what it would cost to prevent it is where preventive care earns its place as one of the most underused levers in healthcare economics.
The cost of waiting
Reactive medicine is expensive medicine. By the time a patient with undiagnosed Type 2 diabetes presents in an emergency department, the cost equation has already turned against everyone—the patient, the payer, and the system. Cardiovascular disease alone costs the U.S. healthcare system around $254 billion annually, with another $168 billion lost in productivity, and that figure is projected to approach $2 trillion by 2050.
Preventive care interrupts that trajectory. Routine screenings, immunizations, blood pressure checks, cancer screenings, and lifestyle counseling shrink the size and complexity of the treatments needed downstream. As the American Medical Association put it earlier this year, preventive services lower long-term costs by “narrowing the scope and invasiveness of treatment plans” before disease becomes severe.
What the evidence actually shows
It’s worth being precise here, because preventive care is sometimes oversold. Not every screening saves money in the narrow sense: a systematic review of clinical preventive services found that while many interventions deliver excellent value (typically under $50,000 per quality-adjusted life year), only a handful—childhood immunizations and low-dose aspirin counselling among them—are unambiguously cost-saving in the short term.
The longer-term picture is far more compelling. A 2026 policy brief on prevention spending noted that decades of evidence confirm preventive healthcare is both effective and a strong long-term investment, but that healthcare organisations consistently underinvest because they’re optimising for short-term budgets.
That mismatch between when prevention costs money (now) and when it saves money (years later) is the single biggest reason we underuse it.
Where preventive care delivers the clearest ROI
Three areas stand out:
- Chronic disease management. Hypertension, diabetes, and high cholesterol are the most expensive, most prevalent, and most preventable conditions in the system. Early identification and consistent management dramatically reduce hospitalizations, which are the single largest driver of cost in conditions like heart failure.
- Cancer screening. Catching cancer at stage 1 versus stage 4 isn’t just a survival difference; it’s an order-of-magnitude difference in cost of care.
- Behavioural and lifestyle interventions. Smoking cessation alone could eliminate a meaningful share of the $240 billion in annual healthcare spending tied to smoking-related illness.
The strategic takeaway for physician groups
In short, practices that build preventive workflows into their care model see lower downstream complication rates, stronger value-based contract performance, and better patient retention. In a payment landscape increasingly tilted toward outcomes rather than volume, prevention has shifted from a public-health ideal to a competitive advantage.
Building a practice model that makes prevention pay off?
Vector Medical Group helps physician groups, hospitals, and investors design care models, operational workflows, and value-based strategies that deliver better outcomes and stronger margins. Get in touch to start the conversation.